Next Article in Journal
SET Overexpression is Associated with Worse Recurrence-Free Survival in Patients with Primary Breast Cancer Receiving Adjuvant Tamoxifen Treatment
Next Article in Special Issue
Metformin Decreases Risk of Tuberculosis Infection in Type 2 Diabetes Patients
Previous Article in Journal
Clinical and Histopathologic Features of Interstitial Lung Disease in Erdheim–Chester Disease
Previous Article in Special Issue
Idiopathic Pulmonary Fibrosis (IPF): An Overview

Proteases and Their Inhibitors in Chronic Obstructive Pulmonary Disease

Biological Sciences and Technology Division, CSIR-North East Institute of Science and Technology, Jorhat 785006, Assam, India
Centre for Biotechnology and Bioinformatics, Dibrugarh University, Dibrugarh 786004, Assam, India
Airway Innate Immunity Research Group, Centre for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen’s University Belfast, Belfast, Northern Ireland BT9 7BL, UK
Author to whom correspondence should be addressed.
J. Clin. Med. 2018, 7(9), 244;
Received: 30 July 2018 / Revised: 24 August 2018 / Accepted: 25 August 2018 / Published: 28 August 2018
In the context of respiratory disease, chronic obstructive pulmonary disease (COPD) is the leading cause of mortality worldwide. Despite much development in the area of drug development, currently there are no effective medicines available for the treatment of this disease. An imbalance in the protease: Antiprotease ratio in the COPD lung remains an important aspect of COPD pathophysiology and several studies have shown the efficacy of antiprotease therapy in both in vitro and in vivo COPD models. However more in-depth studies will be required to validate the efficacy of lead drug molecules targeting these proteases. This review discusses the current status of protease-directed drugs used for treating COPD and explores the future prospects of utilizing the potential of antiprotease-based therapeutics as a treatment for this disease. View Full-Text
Keywords: chronic obstructive pulmonary disease; protease; antiprotease chronic obstructive pulmonary disease; protease; antiprotease
Show Figures

Figure 1

MDPI and ACS Style

Dey, T.; Kalita, J.; Weldon, S.; Taggart, C.C. Proteases and Their Inhibitors in Chronic Obstructive Pulmonary Disease. J. Clin. Med. 2018, 7, 244.

AMA Style

Dey T, Kalita J, Weldon S, Taggart CC. Proteases and Their Inhibitors in Chronic Obstructive Pulmonary Disease. Journal of Clinical Medicine. 2018; 7(9):244.

Chicago/Turabian Style

Dey, Tapan, Jatin Kalita, Sinéad Weldon, and Clifford C. Taggart 2018. "Proteases and Their Inhibitors in Chronic Obstructive Pulmonary Disease" Journal of Clinical Medicine 7, no. 9: 244.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop